David J. Gottlieb

David J. Gottlieb

Hawkesbury Road
Westmead, NSW 2145, Australia

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 129 publications

Third-Party Viral Specific T Cells for Immunocompromised Hosts and Access Barriers: A Review and Commentary by an Expert Panel from ASTCT.

Third-Party Viral Specific T Cells for Immunocompromised Hosts and Access Barriers: A Review and Commentary by an Expert Panel from ASTCT.

Journal: Transplantation and cellular therapy

Published: April 19, 2026

Third-Party Viral Specific T cells for Immunocompromised Hosts and Access Barriers: A Review and Commentary by an Expert Panel from ASTCT.

Third-Party Viral Specific T cells for Immunocompromised Hosts and Access Barriers: A Review and Commentary by an Expert Panel from ASTCT.

Journal: Transplantation and cellular therapy

Published: April 19, 2026

Valganciclovir for CMV Prophylaxis After PTCy-Based Allogeneic Hematopoietic Cell Transplantation.

Valganciclovir for CMV Prophylaxis After PTCy-Based Allogeneic Hematopoietic Cell Transplantation.

Journal: Transplantation and cellular therapy

Published: April 06, 2026

Valganciclovir for CMV Prophylaxis After PTCy-Based Allogeneic Hematopoietic Cell Transplantation.

Valganciclovir for CMV Prophylaxis After PTCy-Based Allogeneic Hematopoietic Cell Transplantation.

Journal: Transplantation and cellular therapy

Published: April 06, 2026

Immune cell subsets that predict cytomegalovirus reactivation magnitude after haematopoietic stem cell transplantation.

Immune cell subsets that predict cytomegalovirus reactivation magnitude after haematopoietic stem cell transplantation.

Journal: Blood

Published: February 13, 2026

Allogeneic stem cell transplantation for mantle cell lymphoma can achieve durable remission and myeloablative conditioning is associated with inferior survival: an Australian and New Zealand Transplant & Cellular Therapies registry study.

Allogeneic stem cell transplantation for mantle cell lymphoma can achieve durable remission and myeloablative conditioning is associated with inferior survival: an Australian and New Zealand Transplant & Cellular Therapies registry study.

Journal: Internal medicine journal

Published: February 01, 2026

Baseline Patient Characteristics and Transplant-Related Factors Predicting Post-Transplant Spirometry Decline and Recovery in Allogeneic Hematopoietic Stem Cell Transplant Recipients.

Baseline Patient Characteristics and Transplant-Related Factors Predicting Post-Transplant Spirometry Decline and Recovery in Allogeneic Hematopoietic Stem Cell Transplant Recipients.

Journal: Transplantation and cellular therapy

Published: January 14, 2026

Prime editing enables drug-controllable T-cell therapies with clinical immunosuppression.

Prime editing enables drug-controllable T-cell therapies with clinical immunosuppression.

Journal: Blood

Published: January 12, 2026

Human Cytomegalovirus Infection in Haematopoietic Stem Cell Transplant Recipients and CAR-T Cell Recipients-PART 2: Antiviral Therapy and Virus-Specific T Cell Therapy for HCMV in Allo-HSCT.

Human Cytomegalovirus Infection in Haematopoietic Stem Cell Transplant Recipients and CAR-T Cell Recipients-PART 2: Antiviral Therapy and Virus-Specific T Cell Therapy for HCMV in Allo-HSCT.

Journal: Reviews in medical virology

Published: November 12, 2025

Human Cytomegalovirus Infection in Haematopoietic Stem Cell Transplant Recipients and CAR T Cell Recipients - PART 1: Risk Factors, Clinical Impact and Immune Response.

Human Cytomegalovirus Infection in Haematopoietic Stem Cell Transplant Recipients and CAR T Cell Recipients - PART 1: Risk Factors, Clinical Impact and Immune Response.

Journal: Reviews in medical virology

Published: November 12, 2025

HAT-PCR Enables Sensitive Quantification of Minimal Residual Disease in Chronic Lymphocytic Leukemia and Myeloma.

HAT-PCR Enables Sensitive Quantification of Minimal Residual Disease in Chronic Lymphocytic Leukemia and Myeloma.

Journal: International journal of molecular sciences

Published: June 20, 2025

Graft-versus-Host Disease Prophylaxis with Cyclophosphamide and Cyclosporin.

Graft-versus-Host Disease Prophylaxis with Cyclophosphamide and Cyclosporin.

Journal: The New England journal of medicine

Published: June 13, 2025

Showing 1-12 of 129

Last Updated: 09/26/2026